Polycythemia vera (PV)
Keywords:
Polycythemia veraAbstract
-
Downloads
References
Thiele J, Kvasnicka HM, Orazi A, Tefferi A, Birgegard G, Barbui T. Polycythemia vera. In: Swerdlow SH, Campo E, Harris NL, et al, editors. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2017. p.39-43.
Greer JP, Foerster J, Rodgers GM, et al, eds. Wintrobe’s Clinical Hematology Textbook, 12th edition. Lippincott Williams & Wilkins, Philadelphia, USA; 2009.
Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome - negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057-69.
Tefferi A, Rumi E, Finazzi G, Vannucchi AM, Rodeghiero F, Randi ML, et al. Survival and prognosis among 1,545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874-81.
Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22-33.
Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114-24.
Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: Final results of a randomized trial initiated in 1980. J Clin Oncol. 2011;29:3907-13.
Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010;148:961-3.
Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426-35.
Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol. 2017;18:88-99.
Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, et al. Efficacy and safety of pegylated interferon alpha-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV): results of a phase 2 study after a 7-year median follow-up. Lancet Haematol. 2017;4:e165-75.
Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019;134:1498-509.
Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, Merup M, et al. A phase II trial of pegylated interferon -2b therapy for polycythemia vera and essential thrombocythemia: Feasibility, clinical and biologic effects, and impact on quality of life. Cancer. 2006;106:2397-405.
Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva- Kyuchukova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): A randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7:e196-208.
